|Giovanni Gorgoni, Commissario Straordinario
“Giovanni Gorgoni, is an economist with degrees in Business Economics, Healthcare Management, and Facility Management.
He has always worked in the health sector, but in different roles: advisor, private and public manager, professor.His professional interests are public health, health communication, healthcare management, network and pathway designing, e-Health, and care intelligence.
Since December 2016 he has been Chief Executive Officer of AReSS (Agenzia Regionale Strategica per la Salute e il Sociale Puglia), the Apulia government agency for strategic planning in health and social policies and for exploration in healthcare processes and technology. In this role he has designed and developed four clinical networks (cancer, stroke, heart and trauma), implemented three value-based labs for Apulian Health System (lean healthcare, activity-based funding, integrated clinical pathways) and started the regional project for chronic care (Care Puglia 3.0).
From October 2015 to November 2016 he was Head of Department for Health Promotion, Social Welfare and Sport for All - Apulia Region, accountable for administration of health and social policies for Apulia Region with organisational connection to regional government and annual budget of € 7,2 billion. The main result of this appointment was the whole re-engineering of regional hospital network - 13.000 beds and 60 centers.
From January 2015 to October 2015 he was CEO of Lecce Local Health Authority in Apulia (7.900 employees, 6 hospitals, 148 community care sites and 803.000 citizens). From July 2011 to December 2014 he was CEO of BAT Local Health Authority in Apulia (3.600 employees, 5 hospitals, 48 community care sites and 390.000 citizens). Before July 2011 he served in Lazio Health System as CFO and COO at Viterbo Local Health Authority (2000-2008) and as Chief Facility Officer at Rome/E Local Health Authority (2008-2011). Previously - in Milan - he worked as operations manager in Humanitas Clinical Institute and as healthcare consultant in KPMG Advisory.
Currently he’s member of Executive Board of National Program for Chronic Diseases and professor in Public Management at Bari LUM University. From February 2018 is in the national register of eligible Healthcare CEOs.”
|Gaetano Di Rienzo, Coordinatore Operativo
Specialista in Chirurgia Toracica (Università Federico II di Napoli) e Chirurgia Generale (Università di Bari).
Frequenza all’estero per due anni presso la Thoraxklinik dell’Università di Heidelberg.
Direttore della U.O.C. di Chirurgia Toracica dell’Ospedale “V. Fazzi” della ASL Lecce dall’1/2/2004.
Nel 2006 fondatore del Gruppo Multidisciplinare di Oncologia Toracica, soprannominato LUNG UNIT (primo Gruppo in Puglia, uno dei primi in Italia), presso l’Ospedale “Fazzi” (cofondatore dott. Vito Lorusso).
Direttore Dipartimento Integrato di Oncologia dell’Area Vasta Salento (ASL Lecce + Ente Ecclesiastico Ospedale di Tricase) dal dicembre 2017.
Casistica operatoria personale complessiva (nelle varie strutture in cui ho lavorato) di oltre 2000 interventi di chirurgia toracica, chirurgia delle neoplasie polmonari, open e VATS lobectomie polmonari, chirurgia open e VATS del mediastino, chirurgia del distretto cervico-mediastinico, chirurgia della tiroide, chirurgia della parete toracica, chirurgia della pleura.
Autore di oltre 100 pubblicazioni scientifiche, la maggioranza delle quali in tema di oncologia toracica, e alcune pubblicate su prestigiosi giornali internazionali.
Presidente della Società Italiana di Endoscopia Toracica (SIET) nel biennio 2017/2019.
Membro del Consiglio Direttivo della Società Italiana di Chirurgia Toracica (SICT) dal 2014 al 2016.
La Chirurgia Toracica del Fazzi è fra i primi 5 Centri Italiani per la chirurgia toracica maggiore mini-invasiva; è inserita come Centro di riferimento nel Master di Chirurgia Toracica mini-invasiva dell’Università di L’Aquila-Teramo e della Scuola di Chirurgia Toracica Mini-Invasiva della Società Italiana di Chirurgia Toracica (ISMITS).
La Chirurgia Toracica del Fazzi ha organizzato dal 2004, anno dell’inizio della mia Direzione, 13 Congressi e Corsi che hanno visto la partecipazione della gran maggioranza dei chirurghi toracici Italiani, oltre che un notevole numero di Pneumologi, Oncologi, Radioterapisti, Medici Nucleari e altri specialisti del settore dell’Oncologia Toracica.
Abbiamo organizzato 6 Corsi di Chirurgia Toracica mini-invasiva (VATS lobectomia), a partire dal 2014, con interventi in diretta eseguiti da me e dai miei Colleghi, cui hanno partecipato chirurghi toracici da tutta Italia.
Il 28-30 settembre 2017 abbiamo organizzato a Lecce il XIX° Congresso Nazionale della Società Italiana di Endoscopia Toracica, cui hanno partecipato 250 Chirurghi Toracici, Pneumologi e specialisti vari.
|Pellegrino Musto, Direttore Scientifico IRCCS CROB Rionero
in Vulture (PZ)
Born in 1956, Dr. Pellegrino Musto is currently Scientific Director at the Referral Cancer Center of Basilicata/Centro di Riferimento Oncologico della Basilicata” (IRCCS-CROB), an OECI recognized Clinical Cancer Center, in Rionero in Vulture (Pz), Italy (since April, 2013).
Dr. Musto received his Medical Degree “summa cum laude” from Naples University in 1982 and was Board Certified “summa cum laude” in Hematology and Medical Oncology at the Ferrara University in 1985 and 1989, respectively. Here he completed his Research Fellowship in Hematology, from 1982 to 1984.
In 1985, Dr. Musto became a Hematology staff member at the IRCCS “Casa Sollievo della Sofferenza” Hospital, in S.Giovanni Rotondo (Fg), Italy, where he progressively held the positions of Senior Assistant, responsible of the “Biology and Therapy of Chronic Hematological Malignancies” Unit and Chief of the Hematology and Day-Hospital Units until 2005.
In February, 2006, he joined the IRCCS-CROB as Director of the Unit of Hematology and Stem Cell Transplantation and Head of the Onco-Hematology Department (since 2008), until March, 2013. Dr. Musto is currently in a time-off work, due to the current role of Scientific Director in the same Institute.
He also obtained a Master in “Management of Health Services in Hematology” at the ISTUD Institute of Stresa, Italy, in 2006, and a Master in “Management of Complex Structures in National Health Service (Tor Vergata University, Rome, and Basilicata region, 2011).
Deeply interested in clinical and translational research, Dr. Musto is a frequently invited speaker and has been involved, as principal investigator or co-investigator, in a large number of national and international clinical trials on new drugs. His main interests focus on prognostic, developmental therapeutics and biological aspects of many hematological diseases including, in particular, plasma cell disorders and myelodysplastic syndromes.
He has so far published 368 articles in the field of hematologic diseases in peer-reviewed international journals covered by PubMed, including New England Journal of Medicine, Lancet, Lancet Oncology, Journal of Clinical Oncology, Blood, Leukemia, Oncogene, Clinical Cancer Research, Cancer, Bone Marrow Transplantation, Haematologica, British Journal of Haematology, and others. Of note, Dr. Musto has recently contributed to the development of international guidelines in the field of monoclonal gammopathies and multiple myeloma, within the context of’ European Myeloma Network (EMN) and of International Myeloma Working Group (IMWG). His current H-index is 56, with 11.797 citations (Scopus, May, 4, 2018; ORCID 0000-0003-3277-6594). He also authored around 500 scientific abstracts (poster or oral presentations) at national or international congresses, as well as several chapters and reviews of hematological interest.
Member, within the Italian Cooperative group GIMEMA, of Multiple Myeloma (2007-2016) and Myelodyplastic Syndromes (since 2011) Working Parties, Dr. Musto is currently member of EMN Italian Board (since 2017) and has been also involved in several other scientific Advisory Boards, as well as in Steering, Writing and Ethic Committees. He also currently coordinates or supervises several institutional research projects in hematological malignancies and has been recipient of research grants and of several financial supports from the Italian Ministry of Health and Pharmaceutical Companies .
After his election in 2009 to the Executive Board of the Italian Society of Hematology (SIE (confirmed until December, 2017), Dr. Musto was appointed Vice-President of this Society from 2010 to 2013. Starting in 2014, he is the coordinator for the development program of SIE Italian Guidelines for myelodysplastic syndromes and member of the National Committee for formative activities. From April, 2015, he is President of SIE Committee that interacts with the Italian Association of Tumor Registries (AIRTUM). In October, 2016, Dr. Musto has been elected in the Executive Board of the Italian Society of Experimental Hematology (SIES). Along with SIE and SIES, his memberships of Scientific Societies also include the American Societies of Hematology (ASH) and of Clinical Oncology (ASCO), the European Haematology Association (EHA) and AIRTUM.
Dr. Musto has served as reviewer for several international journals, such as Lancet Oncology, Journal of Clinical Oncology, Clinical Cancer Research, Annals of Oncology, Haematologica, Cancer, The Oncologist, Bone Marrow Transplantation, British Journal of Haematology, Leukemia and Lymphoma, Leukemia Research, European Journal of Haematology, Annals of Hematology, Expert Opinion Journals, and others. He is currently member of the Editorial Board of Leukemia Research and has reviewed abstracts presented at ASH, EHA, SIE, SIES and IMW meetings.
In 2011, Dr. Musto was among the founder members of the Italian Foundation of Myelodysplastic syndromes (FISM). In 2013 he became member of the Governing Council of “Alliance against Cancer” (a national association which includes all the Oncologic Scientific Institutes in Italy), and of the PhD Committee for Molecular Medicine and Pharmacology at the University of Ferrara.
On December, 2017, he received the National Scientific Qualification (MIUR) for Full Professor position (Hematology), valid until 2023.